| Rituximab |
EU/1/17/1185/003 |
Rixathon, Concentrate for solution for infusion, 500 mg/50 ml, -, Pack: 1 vial |
Sandoz GmbH, Австрия |
Sandoz GmbH, Австрия |
1393.84 |
278.77 |
1672.61 |
4% |
10 |
1403.84 |
280.77 |
1684.61 |
16% |
25 |
1428.84 |
285.77 |
1714.61 |
|
НСР-17165/01.11.2018 предварително изпълнение |
01.11.2018 |
02.11.2018 |
Активен |
16315 |
| Rituximab |
EU/1/17/1185/003 |
Rixathon, Concentrate for solution for infusion, 500 mg/50 ml, -, Pack: 1 vial |
Sandoz GmbH, Австрия |
Sandoz GmbH, Австрия |
1393.84 |
278.77 |
1672.61 |
4% |
10 |
1403.84 |
280.77 |
1684.61 |
16% |
25 |
1428.84 |
285.77 |
1714.61 |
|
НСР-17165/01.11.2018 предварително изпълнение |
01.11.2018 |
02.11.2018 |
Неактивен |
16315 |
| Risedronate |
5912/ 30.09.2009 |
Rizida, Film coated tablet, 35, mg, Pack: 4 |
Тева Фармасютикълс България ЕООД, България |
TEVA Pharmaceutical Works Private Limited Company, Hungary; TEVA Pharmaceutical Works Private Limited Company, Hungary; TEVA UK Ltd., United Kingdom; Pharmachemie B.V., The Netherlands; IVAX Pharmaceuticals s.r.o., Czech Republic |
2.35 |
0.47 |
2.82 |
7% |
0.16 |
2.51 |
0.5 |
3.01 |
20% |
0.47 |
2.98 |
0.6 |
3.58 |
Цената се заличена с Решение НСР-5495/23.01.2015 ; Допуска предварително изпълнение с Решение НСР-5570/29.01.2015 |
НСР-3441/30.04.2014 |
22.05.2014 |
22.05.2014 |
Заличен |
2770 |
| Risedronate |
5912/ 30.09.2009 |
Rizida, Film coated tablet, 35, mg, Pack: 4 |
Тева Фармасютикълс България ЕООД, България |
TEVA Pharmaceutical Works Private Limited Company, Hungary; TEVA Pharmaceutical Works Private Limited Company, Hungary; TEVA UK Ltd., United Kingdom; Pharmachemie B.V., The Netherlands; IVAX Pharmaceuticals s.r.o., Czech Republic |
2.91 |
0.58 |
3.49 |
7% |
0.2 |
3.11 |
0.62 |
3.73 |
20% |
0.58 |
3.69 |
0.74 |
4.43 |
|
КЦРР-2313/20.02.2013 |
07.03.2013 |
07.03.2013 |
Неактивен |
2770 |
| Risedronate |
5912/ 30.09.2009 |
Rizida, Film coated tablet, 35, mg, Pack: 4 |
Тева Фармасютикълс България ЕООД, България |
TEVA Pharmaceutical Works Private Limited Company, Hungary; TEVA Pharmaceutical Works Private Limited Company, Hungary; TEVA UK Ltd., United Kingdom; Pharmachemie B.V., The Netherlands; IVAX Pharmaceuticals s.r.o., Czech Republic |
9.92 |
1.98 |
11.9 |
7% |
0.69 |
10.61 |
2.12 |
12.73 |
20% |
1.98 |
12.59 |
2.52 |
15.11 |
|
КЦРР-680/31.05.2012 |
14.06.2012 |
14.06.2012 |
Неактивен |
2770 |
| Risedronate |
5912/30.09,2009 |
Rizida, Film coated tablet, 35, mg, Pack: 4 |
Тева Фармасютикълс България ЕООД, България |
TEVA Pharmaceutical Works Private Limited Company, Hungary; TEVA Pharmaceutical Works Private Limited Company, Hungary; TEVA UK Ltd., United Kingdom; Pharmachemie B.V., The Netherlands; Teva Czech Industries s.r.o., Czech Republic; Teva Sante - France |
19.54 |
3.91 |
23.45 |
8% |
1.56 |
21.1 |
4.22 |
25.32 |
20% |
3.91 |
25.01 |
5 |
30.01 |
промяна на обстоятелства КЦ-1326/28.01.2010; КЦPP-481/19.04.2012 |
КЦ-491/04.02.2009 |
19.02.2009 |
19.02.2009 |
Неактивен |
2770 |
| Tocilizumab |
EU/1/08/492/007 |
RoActemra, Solution for injection, 162, mg, Pack: 4 pre-filled syringes |
Roche Registration GmbH, Германия |
Roche Pharma AG - Germany |
1563.84 |
312.77 |
1876.61 |
4% |
10 |
1573.84 |
314.77 |
1888.61 |
16% |
25 |
1598.84 |
319.77 |
1918.61 |
Промяна на обстоятелствата НСР-15981/22.06.2018. |
НСР-6424/12.06.2015.; НСР-13341/28.07.2017; НСР-16870/28.09.2018; НСР-20223/22.11.2019 Предварително изпълнение |
22.11.2019 |
02.01.2020 |
Активен |
3260 |
| Tocilizumab |
EU/1/08/492/007 |
RoActemra, Solution for injection, 162, mg, Pack: 4 pre-filled syringes |
Roche Registration GmbH, Германия |
Roche Pharma AG - Germany |
1563.84 |
312.77 |
1876.61 |
4% |
10 |
1573.84 |
314.77 |
1888.61 |
16% |
25 |
1598.84 |
319.77 |
1918.61 |
Промяна на обстоятелствата НСР-15981/22.06.2018. |
НСР-6424/12.06.2015.; НСР-13341/28.07.2017; НСР-16870/28.09.2018; НСР-20223/22.11.2019 Предварително изпълнение* |
22.11.2019 |
02.12.2019 |
Неактивен |
3260 |
| Tocilizumab |
EU/1/08/492/007 |
RoActemra, Solution for injection, 162, mg, Pack: 4 pre-filled syringes |
Roche Registration GmbH, Германия |
Roche Pharma AG - Germany |
1600.59 |
320.12 |
1920.71 |
4% |
10 |
1610.59 |
322.12 |
1932.71 |
16% |
25 |
1635.59 |
327.12 |
1962.71 |
Промяна на обстоятелствата НСР-15981/22.06.2018. |
НСР-6424/12.06.2015.; НСР-13341/28.07.2017; НСР-16870/28.09.2018 |
13.10.2018 |
02.11.2018 |
Неактивен |
3260 |
| Tocilizumab |
EU/1/08/492/007 |
RoActemra, Solution for injection, 162, mg, Pack: 4 pre-filled syringes |
Roche Registration GmbH, Германия |
Roche Pharma AG - Germany |
1600.59 |
320.12 |
1920.71 |
4% |
10 |
1610.59 |
322.12 |
1932.71 |
16% |
25 |
1635.59 |
327.12 |
1962.71 |
Промяна на обстоятелствата НСР-15981/22.06.2018. |
НСР-6424/12.06.2015.; НСР-13341/28.07.2017; НСР-16870/28.09.2018 |
13.10.2018 |
02.11.2018 |
Неактивен |
3260 |
| Tocilizumab |
EU/1/08/492/007 |
RoActemra, Solution for injection, 162, mg, Pack: 4 pre-filled syringes |
Roche Registration GmbH, Германия |
Roche Pharma AG - Germany |
1600.59 |
320.12 |
1920.71 |
4% |
10 |
1610.59 |
322.12 |
1932.71 |
16% |
25 |
1635.59 |
327.12 |
1962.71 |
Промяна на обстоятелствата НСР-15981/22.06.2018. |
НСР-6424/12.06.2015.; НСР-13341/28.07.2017; НСР-16870/28.09.2018 |
13.10.2018 |
02.11.2018 |
Неактивен |
3260 |
| Tocilizumab |
EU/1/08/ 492/007 |
RoActemra, Solution for injection, 162, mg, Pack: 4 pre-filled syringes |
Roche Registration GmbH, Германия |
Roche Pharma AG - Germany |
1600.65 |
320.13 |
1920.78 |
4% |
10 |
1610.65 |
322.13 |
1932.78 |
16% |
25 |
1635.65 |
327.13 |
1962.78 |
Промяна на обстоятелствата НСР-15981/22.06.2018. |
НСР-6424/12.06.2015.; НСР-13341/28.07.2017 |
12.08.2017 |
02.08.2018 |
Неактивен |
3260 |
| Tocilizumab |
EU/1/08/ 492/007 |
RoActemra, Solution for injection, 162, mg, Pack: 4 pre-filled syringes |
Roche Registration Limited, Обединено Кралство |
Roche Pharma AG - Germany |
1600.65 |
320.13 |
1920.78 |
4% |
10 |
1610.65 |
322.13 |
1932.78 |
16% |
25 |
1635.65 |
327.13 |
1962.78 |
|
НСР-6424/12.06.2015.; НСР-13341/28.07.2017 |
12.08.2017 |
02.09.2017 |
Неактивен |
3260 |
| Tocilizumab |
EU/1/08/ 492/007 |
RoActemra, Solution for injection, 162, mg, Pack: 4 pre-filled syringes |
Roche Registration Limited, Обединено Кралство |
Roche Pharma AG - Germany |
1675.6 |
335.12 |
2010.72 |
4% |
10 |
1685.6 |
337.12 |
2022.72 |
16% |
25 |
1710.6 |
342.12 |
2052.72 |
|
НСР-6424/12.06.2015. |
26.06.2015 |
26.06.2015 |
Неактивен |
3260 |
| Tocilizumab |
EU/1/08/492/007 |
RoActemra, Solution for injection, 162, mg, Pack: 4 pre-filled syringes |
Roche Registration Limited, Обединено Кралство |
Roche Pharma AG - Germany |
1795.86 |
359.17 |
2155.03 |
4% |
10 |
1805.86 |
361.17 |
2167.03 |
16% |
25 |
1830.86 |
366.17 |
2197.03 |
|
НСР-4826/ 13.10.2014 |
27.10.2014 |
27.10.2014 |
Неактивен |
3260 |
| Tocilizumab |
EU/1/08/4 92/009 |
RoActemra, Solution for injection, 162, mg, Pack: 4 pre-filled pens |
Roche Registration GmbH, Германия |
Roche Pharma AG, Germany |
1563.84 |
312.77 |
1876.61 |
4% |
10 |
1573.84 |
314.77 |
1888.61 |
16% |
25 |
1598.84 |
319.77 |
1918.61 |
|
НСР-16864/28.09.2018; НСР-20222/22.11.2019 Предварително изпълнение |
22.11.2019 |
02.01.2020 |
Активен |
16292 |
| Tocilizumab |
EU/1/08/4 92/009 |
RoActemra, Solution for injection, 162, mg, Pack: 4 pre-filled pens |
Roche Registration GmbH, Германия |
Roche Pharma AG, Germany |
1563.84 |
312.77 |
1876.61 |
4% |
10 |
1573.84 |
314.77 |
1888.61 |
16% |
25 |
1598.84 |
319.77 |
1918.61 |
|
НСР-16864/28.09.2018; НСР-20222/22.11.2019 Предварително изпълнение* |
22.11.2019 |
02.12.2019 |
Неактивен |
16292 |
| Tocilizumab |
EU/1/08/4 92/009 |
RoActemra, Solution for injection, 162, mg, Pack: 4 pre-filled pens |
Roche Registration GmbH, Германия |
Roche Pharma AG, Germany |
1647.81 |
329.56 |
1977.37 |
4% |
10 |
1657.81 |
331.56 |
1989.37 |
16% |
25 |
1682.81 |
336.56 |
2019.37 |
|
НСР-16864/28.09.2018 |
13.10.2018 |
02.11.2018 |
Неактивен |
16292 |
| Tocilizumab |
EU/1/08/4 92/009 |
RoActemra, Solution for injection, 162, mg, Pack: 4 pre-filled pens |
Roche Registration GmbH, Германия |
Roche Pharma AG, Germany |
1647.81 |
329.56 |
1977.37 |
4% |
10 |
1657.81 |
331.56 |
1989.37 |
16% |
25 |
1682.81 |
336.56 |
2019.37 |
|
НСР-16864/28.09.2018 |
13.10.2018 |
02.11.2018 |
Неактивен |
16292 |
| Tocilizumab |
EU/1/08/492/003 |
RoActemra, Concentrate for solution for infusion, 20 mg/ml - 10 ml, mg, Pack: 1 |
Roche Registration GmbH, Германия |
Roche Pharma AG Germany |
514.91 |
102.98 |
617.89 |
4% |
10 |
524.91 |
104.98 |
629.89 |
16% |
25 |
549.91 |
109.98 |
659.89 |
Промяна на обстоятелствата НСР-15987/22.06.2018. |
НСР-5077/21.11.2014; НСР-13342/28.07.2017 |
12.08.2017 |
02.08.2018 |
Активен |
3377 |
| Tocilizumab |
EU/1/08/492/003 |
RoActemra, Concentrate for solution for infusion, 20 mg/ml - 10 ml, mg, Pack: 1 |
Roche Registration GmbH, Германия |
Roche Pharma AG Germany |
514.91 |
102.98 |
617.89 |
4% |
10 |
524.91 |
104.98 |
629.89 |
16% |
25 |
549.91 |
109.98 |
659.89 |
Промяна на обстоятелствата НСР-15987/22.06.2018. |
НСР-5077/21.11.2014; НСР-13342/28.07.2017 |
12.08.2017 |
02.08.2018 |
Неактивен |
3377 |
| Tocilizumab |
EU/1/08/492/005 |
RoActemra, Concentrate for solution for infusion, 20 mg/ml - 20 ml, mg, Pack: 1 |
Roche Registration GmbH, Германия |
Roche Pharma AG Germany |
1029.82 |
205.96 |
1235.78 |
4% |
10 |
1039.82 |
207.96 |
1247.78 |
16% |
25 |
1064.82 |
212.96 |
1277.78 |
Промяна на обстоятелствата НСР-15986/22.06.2018. |
НСР-5078/21.11.2014; НСР-10019/18.08.2016; НСР-14455/17.11.2017 |
02.12.2017 |
02.08.2018 |
Активен |
3378 |
| Tocilizumab |
EU/1/08/492/005 |
RoActemra, Concentrate for solution for infusion, 20 mg/ml - 20 ml, mg, Pack: 1 |
Roche Registration GmbH, Германия |
Roche Pharma AG Germany |
1029.82 |
205.96 |
1235.78 |
4% |
10 |
1039.82 |
207.96 |
1247.78 |
16% |
25 |
1064.82 |
212.96 |
1277.78 |
Промяна на обстоятелствата НСР-15986/22.06.2018. |
НСР-5078/21.11.2014; НСР-10019/18.08.2016; НСР-14455/17.11.2017 |
02.12.2017 |
02.08.2018 |
Неактивен |
3378 |
| Tocilizumab |
EU/1/08/492/001 |
RoActemra, Concentrate for solution for infusion, 20 mg/ml - 4 ml, mg, Pack: 1 |
Roche Registration GmbH, Германия |
Roche Pharma AG Germany |
205.97 |
41.19 |
247.16 |
4% |
8.24 |
214.21 |
42.84 |
257.05 |
16% |
25 |
239.21 |
47.84 |
287.05 |
Промяна на обстоятелствата НСР-15983/22.06.2018. |
НСР-5076/21.11.2014; НСР-10018/18.08.2016; НСР-14456/17.11.2017 |
02.12.2017 |
02.08.2018 |
Активен |
3376 |
| Tocilizumab |
EU/1/08/492/001 |
RoActemra, Concentrate for solution for infusion, 20 mg/ml - 4 ml, mg, Pack: 1 |
Roche Registration GmbH, Германия |
Roche Pharma AG Germany |
205.97 |
41.19 |
247.16 |
4% |
8.24 |
214.21 |
42.84 |
257.05 |
16% |
25 |
239.21 |
47.84 |
287.05 |
Промяна на обстоятелствата НСР-15983/22.06.2018. |
НСР-5076/21.11.2014; НСР-10018/18.08.2016; НСР-14456/17.11.2017 |
02.12.2017 |
02.08.2018 |
Неактивен |
3376 |